Table 2.
Reasons for Discontinuation and Subsequent Therapy by Treatment Group
| N (%) | Nab-P/S n = 65 | Nab-P/G n = 45 |
|---|---|---|
| Disease progression | 36 (55.4) | 24 (53.3) |
| FOLFIRINOX | 5 (7.7) | 3 (6.7) |
| Nab-paclitaxel plus gemcitabine | 3 (4.6) | – |
| Nab-paclitaxel plus S-1 | – | 2 (4.4) |
| Gemcitabine plus oxaliplatin | 6 (9.2) | 0 |
| S1 plus oxaliplatin | 0 | 2 (4.4) |
| Gemcitabine plus cisplatin | 1a (5.0) | 0 |
| Irinotecan plus S1 | 0 | 2 (4.4) |
| Gemcitabine | 3 (4.6) | 0 |
| S1 | 0 | 1 (2.2) |
| Irinotecan plus trastuzumab | 1b (1.5) | 0 |
| Erlotinib | 1 (1.5) | 0 |
| Anlotinib | 0 | 1 (2.2) |
| Radiotherapy | 0 | 3 (6.7) |
| TACE | 0 | 2 (4.4) |
| Supportive care | 16 (24.6) | 8 (17.8) |
| Doctor discretionc | 11 (16.9) | 7 (15.6) |
| Followed by radiotherapy | 11 (16.9) | 5 (11.1) |
| Followed by surgery | 0 | 2 (4.4) |
| Patient discretiond | 4 (6.2) | 6 (13.3) |
| Other anti-tumor therapy | 2 (3.1) | 2 (4.4) |
| Supportive care | 2 (3.1) | 4 (8.9) |
| Loss to follow-up | 14 (21.5) | 8 (17.8) |
Notes: aA patient with germline BRCA mutation. bA patient with HER2 gene amplification. cWhen patients achieved PR or SD. dWithout evidence of progressive disease.
Abbreviations: Nab-P/S, nab-paclitaxel plus S-1; Nab-P/G, nab-paclitaxel plus gemcitabine; TACE, transarterial chemoembolization.